Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06649708




Registration number
NCT06649708
Ethics application status
Date submitted
3/10/2024
Date registered
21/10/2024
Date last updated
21/11/2024

Titles & IDs
Public title
HX044,FIH Study in Patients With Advanced Solid Tumor Malignancies
Scientific title
A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients With Advanced Solid Tumor Malignancies
Secondary ID [1] 0 0
HX044-I-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumor Malignancies 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - HX044

Experimental: HX044 - Conventional dose-escalation design with 3+3 cohort size. Patients received HX044 treatment at assigned dose level on a Q3 weekly basis.


Treatment: Drugs: HX044
Conventional dose-escalation design with 3+3 cohort size. All administered on a Q3 weekly basis. Dose escalation will be based on the absence of DLTs during the 21-day DLT evaluation after a review of safety data by the Safety Review Escalation Committee. Subjects will continue on study treatment until the subject develops an intolerable toxicity, withdraws consent, develops progression of disease, death, lost to follow-up, start of new anticancer treatment or up to study treatment duration of 24 months, whichever comes first.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants experiencing Adverse Events (AEs)
Timepoint [1] 0 0
All AEs up to 90(±7)days after the last dose of study treatment
Primary outcome [2] 0 0
Number of Participants With Dose-Limiting Toxicities(DLT) of HX044
Timepoint [2] 0 0
At the end of Cycle 2(each cycle is 21±3 days)
Secondary outcome [1] 0 0
Objective response rate (ORR) per Investigator Assessment Using RECIST 1.1 and iRECIST
Timepoint [1] 0 0
Approximately 2 years
Secondary outcome [2] 0 0
Disease control rate(DCR) per Investigator Assessment Using RECIST 1.1 and iRECIST
Timepoint [2] 0 0
Approximately 2 years
Secondary outcome [3] 0 0
Number of participants with positive Anti-Drug Antibody(ADA) of HX044
Timepoint [3] 0 0
Cycle 1,2,3,4,5,6,10,14,18 and then every 8 cycles,Day 1: with 60 minutes before the start of the infusion.
Secondary outcome [4] 0 0
Time of Cmax(Tamx) of HX044
Timepoint [4] 0 0
Approximately 2 years
Secondary outcome [5] 0 0
Terminal Half life( t½) of HX044
Timepoint [5] 0 0
Approximately 2 years
Secondary outcome [6] 0 0
Area Under the serum concentration-time curve(AUC)
Timepoint [6] 0 0
Approximately 2 years

Eligibility
Key inclusion criteria
1. Subjects must voluntarily agree to participate by providing written informed consent and agreeing to comply with protocol and scheduled visit;
2. Male or female subject aged 18-75 years, inclusive;
3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
4. Histologically confirmed advanced malignant solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
5. At least 1 measurable tumor (It is acceptable to allow patients with no measurable lesion but evaluable tumor lesion in the first 2 dose levels in Phase I and at least 1 measurable tumor lesion must be present in Phase IIa) according to RECIST v1.1
6. Life expectancy = 12 weeks.
7. Adequate organ function, as indicated by the following laboratory values: •Hematology (no growth factor and blood transfusion are allowed within 14 days before start of first dose study treatment): Hemoglobin =90g/L Absolute neutrophil count =1.5×109/L Platelet count =100×109/L

* Hepatic: Serum total bilirubin =1.5 × upper limit of normal (ULN); or direct bilirubin =ULN for patients with total bilirubin levels >1.5 × ULN
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 × ULN (ALT and AST = 5 × ULN for subjects with liver metastases)
* Renal:Serum creatinine =1.5 × ULN
* Coagulation: Prothrombin time/international normalized ratio =1.5 × ULN or activated partial thromboplastin time = 1.5 × ULN (for subjects on anticoagulants, prothrombin time or activated partial thromboplastin time must be within the normal range foranticoagulants).
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Prior malignancy active within the previous 5 years except for the tumor for which a subject is enrolled in the study and locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast.
2. Receipt of any anticancer (chemotherapy, radiation therapy, investigational drugs including small molecular inhibitors, endocrine therapy, immunotherapy) therapy within 4 weeks prior to the first dose of study treatment or 5 half-lives of the therapy, whichever is shorter.
3. Severe cardiovascular disease including symptomatic congestive heart failure (New York Heart Association class III or IV), unstable angina, uncontrolled hypertension, cardiac arrhythmia, a history of myocardial infarction within 6 months or a history of arterial thromboembolic event and pulmonary embolism within 3 months of the first dose of investigational agent, as follows:

* QT/QTc interval prolongation (using Fredericia's QT correction formula) at baseline, Female > 470 ms, Male > 450 ms;
* Medications to prolong the QT/QTc interval are currently being taken;
* Family history of long QT syndrome.
4. Patients with a history of or presently experiencing an active autoimmune disease within 2 years of initiating study drug, or those who are at high risk of relapse ; however, subjects with the following are allowed to enroll:

* Type I diabetes that is stable after a fixed dose of insulin or other hypoglycemic;
* Only requiring hormone replacement therapy for autoimmune hypothyroidism;
* Skin disease that does not require systemic treatment such as eczema rash that accounts for <10% of the body surface, psoriasis without ophthalmic symptoms.
5. Subjects who received any major surgery within 4 weeks before the first dose of study treatment (except for diagnostic surgery), and/or subjects who may require major surgery during the study.
6. Lung diseases such as, interstitial lung disease or pneumonia, pulmonary fibrosis, acute lung disease, interstitial pneumonia. Patients with well controlled chronic obstructive pulmonary disease (COPD) are allowed.
7. Subjects with primary central nervous system (CNS) malignancies, symptomatic CNS metastases, symptomatic parenchymal brain leptomeningeal disease or spinal cord compression, except for the following: who has received prior treatment (surgery/radiotherapy) before signing informed consent form (ICF) and is clinically stable for at least 3 months is allowed (prior treatment with corticosteroids are permitted but must stop 14 days before commencing study treatment)
8. Use of any live vaccines within 4 weeks before the first dose of study treatment.
9. A history of psychotropic substance abuse who is unable to quit.
10. Any patient with an uncontrolled illness such as cardiovascular and cerebrovascular diseases, diabetes, high blood pressure, et, and other severe, acute or chronic medical or psychiatric diseases or laboratory abnormalities that, in the Investigator's opinion, may increase the study-related risks or interfere with the interpretation of the findings.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
30/11/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/10/2027
Actual
Sample size
Target
100
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Blacktown Hospital - Blacktown
Recruitment hospital [2] 0 0
Icon Cancer Centre Wesley - Auchenflower
Recruitment hospital [3] 0 0
Cabrini Health Limited - Malvern
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
4066 - Auchenflower
Recruitment postcode(s) [3] 0 0
3144 - Malvern

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hanx Biopharmaceuticals Pty Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The study will consist of a dose-escalation and dose-expansion component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and to evaluate the preliminary antitumor activity of HX044.

HX044 is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA) or any other regulatory authorities for commercial purposes. This is the first study in which HX044 will be given to humans. The study drug has been tested in animals and was found to be well-tolerated with minimal side effects.
Trial website
https://clinicaltrials.gov/study/NCT06649708
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Shuang Liu
Address 0 0
Country 0 0
Phone 0 0
+8618601689862
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06649708